keyword
MENU ▼
Read by QxMD icon Read
search

lupus biologic drug research

keyword
https://www.readbyqxmd.com/read/27837530/freeze-fracture-electron-microscopy-on-domains-in-lipid-mono-and-bilayer-on-nano-resolution-scale
#1
Brigitte Papahadjopoulos-Sternberg
Freeze-fracture electron microscopy (FFEM) as a cryofixation, replica, and transmission electron microscopy technique is unique in membrane bilayer and lipid monolayer research because it enables us to excess and visualize pattern such as domains in the hydrophobic center of lipid bilayer as well as the lipid/gas interface of lipid monolayer. Since one of the preparation steps of this technique includes fracturing the frozen sample and since during this fracturing process the fracture plane follows the area of weakest forces, these areas are exposed allowing us to explore pattern built up by lipids and/or intrinsic proteins but also initiated by peptides, drugs, and toxins reaching into these normally hard to access areas...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27592380/from-old-concerns-to-new-advances-and-personalized-medicine-in-lupus-the-end-of-the-tunnel-is-approaching
#2
Andrea Doria, M Eric Gershwin, Carlo Selmi
The significant decrease in mortality rates worldwide, the increased proportion of patients achieving a durable remission, and the recent approval of a new drug after several decades are encouraging advances in the tangled history of systemic lupus erythematosus (SLE). However, when data are observed more closely, the research findings on disease pathogenesis and targeted treatments have been quite misleading, as illustrated by the central role of B cells but the missed endpoints in rituximab clinical trials which are burdened by the wide variability of SLE manifestations or the ethnic determinants of disease severity...
August 31, 2016: Journal of Autoimmunity
https://www.readbyqxmd.com/read/27510603/clinical-characteristics-of-children-with-membranous-lupus-nephritis-the-childhood-arthritis-and-rheumatology-research-alliance-legacy-registry
#3
A Boneparth, S E Wenderfer, L Nandini Moorthy, S M Radhakrishna, A C P Sagcal-Gironella, E von Scheven
OBJECTIVE: The objective of this article is to describe and compare clinical features, treatment, and renal outcomes of children with membranous lupus nephritis (MLN), through analysis of a national multicenter registry. METHODS: Patients with pediatric systemic lupus erythematosus (SLE) and MLN from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry were included. Demographic, disease and medication-related data were collected between 2010 and 2014 from 59 CARRA Legacy Registry sites...
August 9, 2016: Lupus
https://www.readbyqxmd.com/read/27497254/interferon-targeted-therapy-in-systemic-lupus-erythematosus-is-this-an-alternative-to-targeting-b-and-t-cells
#4
K C Kalunian
Clinical trials of investigational agents in systemic lupus erythematosus (SLE) have focused on targeting dysregulated B and T cells; however, recent translational research findings of the importance of the dysregulation of the innate immune system in SLE have led to clinical trials that target interferon. Three biologics that target type I interferons have been tested for their efficacy and safety in active SLE patients; these phase II trials have tested the hypothesis that down-regulation of interferon-regulated gene expression (the interferon signature) lessen the clinical burden of SLE...
September 2016: Lupus
https://www.readbyqxmd.com/read/27429254/recent-advances-in-the-biologic-therapy-of-lupus-the-10-most-important-areas-to-look-for-common-pitfalls-in-clinical-trials
#5
Jorge Medina-Rosas, Hanan Al-Rayes, Ahmed T Moustafa, Zahi Touma
INTRODUCTION: Systemic lupus erythematosus (SLE) is an autoimmune disease affecting different organs. The improved knowledge of the disease's pathogenesis has contributed to the emergence of immune targets and new biologic drugs directed at them. Although rheumatologists continue to use off-label biologics in SLE resistant to other immunosuppressants, only belimumab has been approved as a biological therapy since 2011. AREAS COVERED: In this review, an overview is provided on: 1) the classification of the biologic drugs in clinical trials and of those under research; 2) the results of clinical trials of biologic therapy with an interpretation of pitfalls and syntheses of potential approaches to overcome these pitfalls and, 3) the commonly used disease activity metrics and composite indices for assessing response to drugs...
October 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/26272032/structure-activity-studies-of-wnt-%C3%AE-catenin-inhibition-in-the-niclosamide-chemotype-identification-of-derivatives-with-improved-drug-exposure
#6
Robert A Mook, Jiangbo Wang, Xiu-Rong Ren, Minyong Chen, Ivan Spasojevic, Larry S Barak, H Kim Lyerly, Wei Chen
The Wnt signaling pathway plays a key role in regulation of organ development and tissue homeostasis. Dysregulated Wnt activity is one of the major underlying mechanisms responsible for many diseases including cancer. We previously reported the FDA-approved anthelmintic drug Niclosamide inhibits Wnt/β-catenin signaling and suppresses colon cancer cell growth in vitro and in vivo. Niclosamide is a multi-functional drug that possesses important biological activity in addition to inhibition of Wnt/β-catenin signaling...
September 1, 2015: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/25213358/biologics-in-autoimmune-diseases
#7
EDITORIAL
Guixiu Shi, Yuan Liu
No abstract text is available yet for this article.
2014: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/24933225/triptolide-progress-on-research-in-pharmacodynamics-and-toxicology
#8
REVIEW
Xiao-Jiaoyang Li, Zhen-Zhou Jiang, Lu-yong Zhang
ETHNOPHARMACOLOGICAL RELEVANCE: Tripterygium wilfordii Hook. f. (Tripterygium wilfordii), also known as Huangteng and gelsemium elegan, is a traditional Chinese medicine that has been marketed in China as Tripterygium wilfordii glycoside tablets. Triptolide (TP), an active component in Tripterygium wilfordii extracts, has been used to treat various diseases, including lupus, cancer, rheumatoid arthritis and nephritic syndrome. This review summarizes recent developments in the research on the pharmacodynamics, pharmacokinetics, pharmacy and toxicology of TP, with a focus on its novel mechanism of reducing toxicity...
August 8, 2014: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/24748859/semantic-modeling-for-snps-associated-with-ethnic-disparities-in-hapmap-samples
#9
Hyoyoung Kim, Won Gi Yoo, Junhyung Park, Heebal Kim, Byeong-Chul Kang
Single-nucleotide polymorphisms (SNPs) have been emerging out of the efforts to research human diseases and ethnic disparities. A semantic network is needed for in-depth understanding of the impacts of SNPs, because phenotypes are modulated by complex networks, including biochemical and physiological pathways. We identified ethnicity-specific SNPs by eliminating overlapped SNPs from HapMap samples, and the ethnicity-specific SNPs were mapped to the UCSC RefGene lists. Ethnicity-specific genes were identified as follows: 22 genes in the USA (CEU) individuals, 25 genes in the Japanese (JPT) individuals, and 332 genes in the African (YRI) individuals...
March 2014: Genomics & Informatics
https://www.readbyqxmd.com/read/24730661/biologic-agents-therapy-for-saudi-children-with-rheumatic-diseases-indications-and-safety
#10
Sulaiman M Al-Mayouf, Abdullatif Alenazi, Hind AlJasser
OBJECTIVE: To report the indications and safety of biologic agents in childhood rheumatic diseases at a tertiary hospital. METHODS: Children with rheumatic diseases treated with biologic agents at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, from January 2001 to December 2011 were included. All patients were reviewed for: demographic characteristics, diagnosis, concomitant treatment and indications of using biologic agents, age at start of therapy and side effects during the treatment period...
June 2016: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/24379267/-prolactin-as-an-immunomodulatory-factor-in-psoriatic-arthritis
#11
REVIEW
Izabela Kokot, Lilla Pawlik-Sobecka, Sylwia Płaczkowska, Agnieszka Piwowar
Prolactin (PRL) is a hormone synthesized and secreted by lactotroph cells in the anterior pituitary gland. There is also extrapituitary hormone secretion by many cells, including cells of the immune system. In physiological conditions PRL is responsible for lactogenesis and other processes associated with it. PRL plays a significant role during the immune response as a cytokine, affecting proliferation and differentiation of many immune system cells. The biological effect of the hormone depends on binding with the specific prolactin receptor PRL-R, and activation of the transcription factors of targeted genes...
2013: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/24238689/current-management-of-lupus-nephritis
#12
REVIEW
Frédéric A Houssiau, Bernard R Lauwerys
Despite decades of clinical research aimed at finding the most appropriate immunosuppressive regime, lupus nephritis (LN) remains one of the major disease manifestations of systemic lupus erythematosus (SLE) with a great impact on survival and quality of life. We start this review by defining the disease burden, the real-world challenges and the poor prognostic factors. We then discuss the current anti-inflammatory, cytotoxic and biologic therapies, with special emphasis on the need for optimal global care.
June 2013: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/24144710/using-registries-to-identify-adverse-events-in-rheumatic-diseases
#13
REVIEW
Geraldina Lionetti, Yukiko Kimura, Laura E Schanberg, Timothy Beukelman, Carol A Wallace, Norman T Ilowite, Jane Winsor, Kathleen Fox, Marc Natter, John S Sundy, Eric Brodsky, Jeffrey R Curtis, Vincent Del Gaizo, Solomon Iyasu, Angelika Jahreis, Ann Meeker-O'Connell, Barbara B Mittleman, Bernard M Murphy, Eric D Peterson, Sandra C Raymond, Soko Setoguchi, Jeffrey N Siegel, Rachel E Sobel, Daniel Solomon, Taunton R Southwood, Richard Vesely, Patience H White, Nico M Wulffraat, Christy I Sandborg
The proven effectiveness of biologics and other immunomodulatory products in inflammatory rheumatic diseases has resulted in their widespread use as well as reports of potential short- and long-term complications such as infection and malignancy. These complications are especially worrisome in children who often have serial exposures to multiple immunomodulatory products. Post-marketing surveillance of immunomodulatory products in juvenile idiopathic arthritis (JIA) and pediatric systemic lupus erythematosus is currently based on product-specific registries and passive surveillance, which may not accurately reflect the safety risks for children owing to low numbers, poor long-term retention, and inadequate comparators...
November 2013: Pediatrics
https://www.readbyqxmd.com/read/23666467/ten-developments-in-the-use-of-biologicals-for-systemic-lupus-erythematosus
#14
REVIEW
Daniel J Wallace
Belimumab has recently been approved, and several other types of biological therapy with different mechanisms of action are currently in phase II and III studies. This review puts these approaches in context, emphasizing mechanistic categories and clinical trial designs. Most of the promising approaches involve B cell depletion or modulation. Post-approval experience with belimumab is critically reviewed.
July 2013: Current Rheumatology Reports
https://www.readbyqxmd.com/read/23541482/cardiovascular-disease-in-autoimmune-rheumatic-diseases
#15
REVIEW
Ivana Hollan, Pier Luigi Meroni, Joseph M Ahearn, J W Cohen Tervaert, Sam Curran, Carl S Goodyear, Knut A Hestad, Bashar Kahaleh, Marcello Riggio, Kelly Shields, Mary C Wasko
Various autoimmune rheumatic diseases (ARDs), including rheumatoid arthritis, spondyloarthritis, vasculitis and systemic lupus erythematosus, are associated with premature atherosclerosis. However, premature atherosclerosis has not been uniformly observed in systemic sclerosis. Furthermore, although experimental models of atherosclerosis support the role of antiphospholipid antibodies in atherosclerosis, there is no clear evidence of premature atherosclerosis in antiphospholipid syndrome (APA). Ischemic events in APA are more likely to be caused by pro-thrombotic state than by enhanced atherosclerosis...
August 2013: Autoimmunity Reviews
https://www.readbyqxmd.com/read/23506880/the-slco-former-slc21-superfamily-of-transporters
#16
REVIEW
Bruno Hagenbuch, Bruno Stieger
The members of the organic anion transporting polypeptide superfamily (OATPs) are classified within the SLCO solute carrier family. All functionally well characterized members are predicted to have 12 transmembrane domains and are sodium-independent transport systems that mediate the transport of a broad range of endo- as well as xenobiotics. Substrates are mainly amphipathic organic anions with a molecular weight of more than 300Da, but some of the known transported substrates are also neutral or even positively charged...
April 2013: Molecular Aspects of Medicine
https://www.readbyqxmd.com/read/22982174/lupus-nephritis-a-critical-review
#17
REVIEW
Andrea T Borchers, Naama Leibushor, Stanley M Naguwa, Gurtej S Cheema, Yehuda Shoenfeld, M Eric Gershwin
Lupus nephritis remains one of the most severe manifestations of systemic lupus erythematosus associated with considerable morbidity and mortality. A better understanding of the pathogenesis of lupus nephritis is an important step in identifying more targeted and less toxic therapeutic approaches. Substantial research has helped define the pathogenetic mechanisms of renal manifestations and, in particular, the complex role of type I interferons is increasingly recognized; new insights have been gained into the contribution of immune complexes containing endogenous RNA and DNA in triggering the production of type I interferons by dendritic cells via activation of endosomal toll-like receptors...
December 2012: Autoimmunity Reviews
https://www.readbyqxmd.com/read/22614721/belimumab-and-the-clinical-data
#18
Katrina Shum, Anca Askanase
Benlysta (belimumab) is a fully human recombinant monoclonal IgG antibody that neutralizes soluble B-lymphocyte stimulator and inhibits its biologic activity. Benlysta was recently approved by the US Food and Drug Administration to treat systemic lupus erythematosus (SLE). The current review discusses the data from the belimumab clinical trials and the role of this new medication in the treatment of SLE. We propose that Benlysta should be used in antinuclear antibody-positive patients with active disease in whom the goal of therapy is to decrease SLE activity, reduce flares, and help lower background medications...
August 2012: Current Rheumatology Reports
https://www.readbyqxmd.com/read/22464040/belimumab-review-of-use-in-systemic-lupus-erythematosus
#19
REVIEW
Eric G Boyce, Bryan E Fusco
BACKGROUND: Belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulating protein, was the first biologic agent approved for, and the first drug approved in 55 years for, the treatment of systemic lupus erythematosus (SLE) by the US Food and Drug Administration (FDA). OBJECTIVE: This article reviews the current research on belimumab and provides recommendations on its use in the treatment of SLE. METHODS: The Cochrane Library, EBSCO, IPA, MEDLINE, and SCOPUS were searched for research published from January 2000 to November 2011, using the search terms belimumab, Benlysta, and Lympho-Stat B...
May 2012: Clinical Therapeutics
https://www.readbyqxmd.com/read/22364138/adverse-cardiovascular-effects-of-antirheumatic-drugs-implications-for-clinical-practice-and-research
#20
REVIEW
Armen Yuri Gasparyan, Lilit Ayvazyan, Giuseppe Cocco, George D Kitas
Clinical manifestations of most rheumatic diseases have changed over the past few decades, largely due to advances in therapies targeting autoimmune and (auto)inflammatory pathways. Improvements in the management of rheumatic diseases have also now brought to the fore the issue of comorbidities. It has become evident that the burden of cardiovascular morbidity and mortality is increased in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and the spondyloarthropathies, amongst other conditions. As a result, efforts have switched toward investigating the effects of conventional antirheumatic and new biologic agents on inflammationinduced atherothrombosis...
2012: Current Pharmaceutical Design
keyword
keyword
28649
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"